Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AGORACOM Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::14877483.png) AGORACOM - George [@AGORACOM](/creator/twitter/AGORACOM) on x 15.1K followers
Created: 2025-07-15 15:59:24 UTC

FDA Submission in Progress for Lucid‑MS Phase X Trial

@QuantumBP  NASDAQ: QNTM / CSE: QNTM

💡 Lead therapy Lucid‑MS successfully completed Phase X trials — no serious side effects reported

✅ FDA submission now in preparation for Phase X clinical trial approval

🧠 Targets myelin protection and repair — a new approach to Multiple Sclerosis beyond immune suppression

⚕️ Advancing a first-in-class neuroprotective therapy for MS patients

![](https://pbs.twimg.com/amplify_video_thumb/1945151207036583936/img/gfNwrwa_xWlEP4ag.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945151219862753550/c:line.svg)

**Related Topics**
[nasdaq](/topic/nasdaq)

[Post Link](https://x.com/AGORACOM/status/1945151219862753550)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

AGORACOM Avatar AGORACOM - George @AGORACOM on x 15.1K followers Created: 2025-07-15 15:59:24 UTC

FDA Submission in Progress for Lucid‑MS Phase X Trial

@QuantumBP NASDAQ: QNTM / CSE: QNTM

💡 Lead therapy Lucid‑MS successfully completed Phase X trials — no serious side effects reported

✅ FDA submission now in preparation for Phase X clinical trial approval

🧠 Targets myelin protection and repair — a new approach to Multiple Sclerosis beyond immune suppression

⚕️ Advancing a first-in-class neuroprotective therapy for MS patients

XXXXX engagements

Engagements Line Chart

Related Topics nasdaq

Post Link

post/tweet::1945151219862753550
/post/tweet::1945151219862753550